Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Baxter
Express Scripts
Boehringer Ingelheim

Last Updated: May 24, 2022

Investigational Drug Information for Danirixin


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Danirixin?

Danirixin is an investigational drug.

There have been 10 clinical trials for Danirixin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 19th 2017.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

There are twenty-eight US patents protecting this investigational drug and three hundred and forty-seven international patents.

Recent Clinical Trials for Danirixin
TitleSponsorPhase
GSK1325756 Relative Bioavailability Study in Healthy Elderly SubjectsGlaxoSmithKlinePhase 1
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)GlaxoSmithKlinePhase 2
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)GlaxoSmithKlinePhase 2

See all Danirixin clinical trials

Clinical Trial Summary for Danirixin

Top disease conditions for Danirixin
Top clinical trial sponsors for Danirixin

See all Danirixin clinical trials

US Patents for Danirixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Danirixin See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Danirixin See Plans and Pricing Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. (New York, NY) See Plans and Pricing
Danirixin See Plans and Pricing JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
Danirixin See Plans and Pricing Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
Danirixin See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Danirixin See Plans and Pricing Therapeutic compounds and compositions, and methods of use thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Danirixin

Drugname Country Document Number Estimated Expiration Related US Patent
Danirixin Australia AU2017261372 2036-05-05 See Plans and Pricing
Danirixin Canada CA3023278 2036-05-05 See Plans and Pricing
Danirixin China CN107847398 2036-05-05 See Plans and Pricing
Danirixin European Patent Office EP3452003 2036-05-05 See Plans and Pricing
Danirixin Hong Kong HK1249728 2036-05-05 See Plans and Pricing
Danirixin Japan JP2019520866 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Baxter
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.